Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Nov 21, 2014; 20(43): 16227-16235
Published online Nov 21, 2014. doi: 10.3748/wjg.v20.i43.16227
Published online Nov 21, 2014. doi: 10.3748/wjg.v20.i43.16227
Figure 1 Serum active glucagon-like peptide-1 concentrations, body weight, food intake or ratio of liver weight to body weight in ob/ob mice and their lean littermates.
A: Serum active glucagon-like peptide-1 (GLP-1) concentrations (pg/mL) in ob/ob mice that were fed either a normal chow diet (ob/ob) or a normal chow diet supplemented with MK-0626 (1.5 mg/kg) (ob/ob + MK 1.5) or MK-0626 (3 mg/kg) (ob/ob + MK 3.0) and their lean littermates fed a normal chow diet (lean). Serum samples were collected at the end of the 8-wk treatment period; B: Changes in body weight in lean, ob/ob, ob/ob + MK 1.5 and ob/ob + MK 3.0 groups during the treatment; C: Changes in food intake in lean, ob/ob, ob/ob + MK 1.5 and ob/ob + MK 3.0 groups during the treatment; D: A comparison of body weight at the end of the 8-wk treatment period; E: A comparison of food intake at the end of the 8-wk treatment period; F: A comparison of the ratio of liver weight to body weight at the end of the 8-wk treatment period. bP < 0.01 vs the lean group; cP < 0.05, dP < 0.01 vs the ob/ob group (n = 16 mice per group).
-
Citation: Ohyama T, Sato K, Yamazaki Y, Hashizume H, Horiguchi N, Kakizaki S, Mori M, Kusano M, Yamada M. MK-0626, a selective DPP-4 inhibitor, attenuates hepatic steatosis in
ob/ob mice. World J Gastroenterol 2014; 20(43): 16227-16235 - URL: https://www.wjgnet.com/1007-9327/full/v20/i43/16227.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i43.16227